-
Techniques in Vascular and... Sep 2023Advancements in minimally invasive technology, coupled with imaging breakthroughs, have empowered the field of interventional radiology to achieve unparalleled precision... (Review)
Review
Advancements in minimally invasive technology, coupled with imaging breakthroughs, have empowered the field of interventional radiology to achieve unparalleled precision in image-guided diagnosis and treatment while simultaneously reducing periprocedural morbidity. Molecular imaging, which provides valuable physiological and metabolic information alongside anatomical localization, can expand the capabilities of image-guided interventions. Among various molecular imaging techniques, positron emission tomography (PET) stands out for its superior spatial resolution and ability to acquire quantitative data. PET has emerged as a crucial tool for oncologic imaging and plays a pivotal role in both staging and the assessment of treatment responses. Typically used in combination with computed tomography (CT) (PET/CT) and occasionally with magnetic resonance imaging MRI (PET/MRI), PET as a hybrid imaging approach offers enhanced insights into disease progression and response. In recent years, PET has also found its way into image-guided interventions, especially within the rapidly expanding field of interventional oncology. This review aims to explore the current and evolving role of metabolic imaging, specifically PET, in interventional oncology. By delving into the unique advantages and applications of PET in guiding oncological interventions and assessing response, we seek to highlight the increasing significance of this modality in the realm of interventional radiology.
Topics: Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed; Multimodal Imaging; Magnetic Resonance Imaging
PubMed: 38071029
DOI: 10.1016/j.tvir.2023.100916 -
Seminars in Radiation Oncology Jan 2021Theranostics is a precision medicine discipline that integrates diagnostic nuclear medicine imaging with radionuclide therapy in a manner that provides both a tumor... (Review)
Review
Theranostics is a precision medicine discipline that integrates diagnostic nuclear medicine imaging with radionuclide therapy in a manner that provides both a tumor phenotype and personalized therapy to patients with cancer using radiopharmaceuticals aimed at the same target-specific biological pathway or receptor. The aim of quantitative nuclear medicine imaging is to plan the alpha or beta-emitting therapy based on an accurate 3-dimensional representation of the in-vivo distribution of radioactivity concentration within the tumor and normal organs/tissues in a noninvasive manner. In general, imaging may be either based on positron emission tomography (PET) or single photon emission computed tomography (SPECT) invariably in combination with X-ray CT (PET/CT; SPECT/CT) or, to a much lesser extent, MRI. PET and SPECT differ in terms of the radionuclides and physical processes that give rise to the emission of high energy photons, as well as the sets of technologies involved in their detection. Using a variety of standardized quantitative parameters, system calibration, patient preparation, imaging acquisition and reconstruction protocols, and image analysis protocols, an accurate quantification of the tracer distribution can be obtained, which helps prescribe the therapeutic dose for each patient.
Topics: Humans; Nuclear Medicine; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon
PubMed: 33246633
DOI: 10.1016/j.semradonc.2020.07.003 -
Annals of Oncology : Official Journal... Jan 2022
Topics: Humans; Immunotherapy; Neoplasms; Positron-Emission Tomography
PubMed: 34808339
DOI: 10.1016/j.annonc.2021.11.003 -
Rheumatology (Oxford, England) May 20222-deoxy-2[18F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a... (Review)
Review
2-deoxy-2[18F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a number of inflammatory cells. Exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wide range of infective and inflammatory diseases. Rheumatological diseases can affect multiple sites within the musculoskeletal system alongside multi-organ extra-articular disease manifestations. Inflammation is central to these diseases, making FDG PET-CT a logical choice. In this review article we describe the various applications of FDG PET-CT in rheumatological diseases using illustrative examples to highlight the beneficial role of FDG PET-CT in each case.
Topics: Fluorodeoxyglucose F18; Glucose; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Rheumatic Diseases
PubMed: 34463703
DOI: 10.1093/rheumatology/keab675 -
Der Radiologe May 2020Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques... (Review)
Review
BACKGROUND
Positron-emission tomography/computed tomography (PET/CT) and positron-emission tomography/magnetic resonance imaging (PET/MRI) are hybrid medical imaging techniques that are becoming increasingly important in the diagnostic workup of cancer. Correct definition and interpretation of results are key challenges for both radiologists/specialists in nuclear medicine as well as for the treating clinician. Strong interdisciplinary communication is prerequisite to solve the upcoming complexity of retrieved information generated by hybrid imaging.
OBJECTIVES
Different indications for hybrid medical imaging and review of current theranostic principles from the perspective of clinicians/clinical oncologists.
MATERIALS AND METHODS
The GBA guidelines and recommendations retrieved from the corresponding German S3 guidelines for the use of PET imaging are summarized, followed by a review of innovative clinical trials that promote PET-based therapeutic strategies and radioligand therapies.
RESULTS
Next generation PET/CT and PET/MRI imaging are being increasingly used for diagnostic purposes and follow-up staging in malignant tumors. Radioligand therapy may have the potential to be a further cornerstone in personalized antitumor therapy.
CONCLUSIONS
Careful implementation of hybrid medical imaging can clearly improve the quality of the diagnosis in cancer patients and even increase the quality of care for cancer patients. Close interdisciplinary collaboration is essential to optimize therapeutic strategies for each patient.
Topics: Humans; Interprofessional Relations; Multimodal Imaging; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiologists
PubMed: 32052117
DOI: 10.1007/s00117-020-00653-x -
Cancer Letters Nov 2022Prostate specific membrane antigen positron emission tomography (PSMA PET) is an excellent molecular imaging technique for prostate cancer. Currently, PSMA PET for... (Review)
Review
Prostate specific membrane antigen positron emission tomography (PSMA PET) is an excellent molecular imaging technique for prostate cancer. Currently, PSMA PET for patients with primary prostate cancer is supplementary to conventional imaging techniques, according to guidelines. This supplementary function of PSMA PET is due to a lack of systematic review of its strengths, limitations, and potential development direction. Thus, we review PSMA ligands, detection, T, N, and M staging, treatment management, and false results of PSMA PET in clinical studies. We also discuss the strengths and challenges of PSMA PET. PSMA PET can greatly increase the detection rate of prostate cancer and accuracy of T/N/M staging, which facilitates more appropriate treatment for primary prostate cancer. Lastly, we propose that PSMA PET could become the first-line imaging modality for primary prostate cancer, and we describe its potential expanded application.
Topics: Gallium Radioisotopes; Humans; Male; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostate; Prostatic Neoplasms
PubMed: 36027998
DOI: 10.1016/j.canlet.2022.215883 -
Rheumatology (Oxford, England) Apr 2022
Topics: Arthritis, Rheumatoid; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Necrosis Factor Inhibitors
PubMed: 34919664
DOI: 10.1093/rheumatology/keab932 -
Zeitschrift Fur Medizinische Physik Feb 2023
Topics: Precision Medicine; Electrons; Positron-Emission Tomography; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Fluorodeoxyglucose F18
PubMed: 36710155
DOI: 10.1016/j.zemedi.2023.01.006 -
PET Clinics Oct 2023Many novel PET radiotracers have demonstrated potential use in breast cancer. Although not currently approved for clinical use in the breast cancer population, these... (Review)
Review
Many novel PET radiotracers have demonstrated potential use in breast cancer. Although not currently approved for clinical use in the breast cancer population, these innovative imaging agents may one day play a role in the diagnosis, staging, management, and even treatment of breast cancer.
Topics: Humans; Female; Breast Neoplasms; Radiopharmaceuticals; Positron-Emission Tomography; Positron Emission Tomography Computed Tomography
PubMed: 37369615
DOI: 10.1016/j.cpet.2023.05.001 -
Methods in Molecular Biology (Clifton,... 2024Positron emission tomography (PET) is one of the most sensitive whole-body molecular imaging techniques available in the clinic, able to detect picomolar levels of...
Positron emission tomography (PET) is one of the most sensitive whole-body molecular imaging techniques available in the clinic, able to detect picomolar levels of probe. As such, it was recently demonstrated that PET could also be used to track single radiolabeled cells in small animals. In this protocol, we present detailed procedures for radiolabeling cells using mesoporous silica nanoparticles (MSNs) and for tracking these cells in real time using in vivo PET. This includes static imaging of single cells as well as dynamic tracking of moving cells directly from the list-mode data. The protocol provides detailed instructions and examples for each step.
Topics: Animals; Positron-Emission Tomography; Nanoparticles; Whole Body Imaging
PubMed: 38006505
DOI: 10.1007/978-1-0716-3499-8_19